Evaluation of Autonomic Nervous System Changes in Response to Stimulation by Sacral Neuromodulation

Sacral Neuromodulation Clinical Trial

— ESTIME  

Official title:

Evaluation of Autonomic Nervous System Changes in Response to Stimulation by Sacral Neuromodulation

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06434831
• Other study ID #: 2023_195
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 2, 2024
• Est. completion date: December 2, 2026

Study information

• Verified date: March 2024
• Source: University Hospital, Lille
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Overactive bladder syndrome (OAB) is defined by urgent and frequent urges to urinate associated with frequent night-time urination and sometimes urinary incontinence. Sacral neuromodulation (SNM) is now one of the second-line treatments for OAB.

The mode of action of SNM is still poorly understood but a number of data from recent scientific literature suggest that SNM may act, among other things, by altering the balance of the autonomic nervous system (ANS) - located at the interface between the urinary tract and the brain structures regulating the functioning of the urinary tract.

The aim of this study would therefore be to develop a predictive tool for the effectiveness of SNM.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: December 2, 2026
• Est. primary completion date: December 2, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male of female = 18 years

• OAB syndrome

• Indication for a two-staged SNM

• Under general anaesthesia with Remifentanil and Propofol

• Patient who has given written consent to participate in the trial

• Patient willing to comply with all study procedures and duration

Exclusion Criteria:

• Tibial neuro-stimulation (last 3 months)

• Sacral neuromodulation (last 3 months)

• Botulinum toxin A intra-detrusor injection (last 9 months)

• Pregnancy in progress

• Administrative reasons

• Guardianship/curatorship

Related Conditions & MeSH terms

• Bladder Hyperactivity
• Hyperkinesis
• Sacral Neuromodulation
• Urinary Bladder, Overactive

Intervention

Device:
• Medical device for SNM: Interstim II, Interstim micro
ANI will be used during the SNM (2 hours)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Lille

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of HFVI analysed through HRV at baseline and during standardized stimulation protocol randomly delivered at the level of the 4contact points of the quadripolar lead at the time of lead implantation between the effective and noneffective groups	Comparison of HFVI (high frequence variability index) analysed through heart rate variability (HRV) at baseline and during a standardized stimulation protocol (14 Hz, 210 mcs, amplitude to elicit anal motor response) randomly delivered at the level of the 4 contact points of the quadripolar lead at the time of lead implantation, between the effective and non-effective groups.	1 year
Secondary	Comparison of other HRV parameters at baseline and during a standardized stimulation protocol randomly delivered at the level of the 4 contact points of the quadripolar lead at the time of lead implantation	Comparison of other HRV parameters (SDNN, RMSSD, HF, LF) at baseline and during a standardized stimulation protocol (14 Hz, 210 mcs, amplitude to elicit anal motor response) randomly delivered at the level of the 4 contact points of the quadripolar lead at the time of lead implantation,	1 year